**Therapeutics and Drug Candidates in Immuno-Oncology**

invIoS, a fully owned subsidiary of APEIRON Biologics AG is a private biotech company based in Vienna, Austria focusing on the discovery and development of immuno-oncology (IO) drugs. invIoS team has a proven track record of successful development and funding of pre-clinical/clinical and up to market cutting-edge projects, small molecule drugs and biologics and is now seeking to in-license novel opportunities for their IO pipeline.

**Areas of Interest**

- Opportunities that directly target the immune system to strengthen its response against cancer
- invIoS is open to most modalities, with a particular interest in small molecules and biologics that actively engage or modulate cells of the immune system to attack and destroy cancer cells
- invIoS is also interested in innovative approaches and novel technologies that could form the basis for developing platforms or platform technologies that allow for the development of multiple drug candidates targeting solid or hematologic malignancies
- All oncology indications are of interest, including orphan diseases

**Out of Scope**

- Cell therapy and gene therapy approaches, drug repurposing and in silico approaches are not of interest

**Developmental Stages of Interest**

- invIoS is open to approaches from the discovery stage through to Clinical Phase II, with a particular interest in projects at the discovery/pre-clinical to pre-IND stage
- Opportunities with proof of concept data (i.e. in vitro or in vivo data) are of high interest

**Submission Information**

- Submission of either this **optional submission form** or alternatively one page, 200-300 word briefs are encouraged, along with any optional supplementary information (e.g. relevant publications, patents, slide decks)
- In submitting to this campaign, you confirm that your submission contains only non-confidential information

**Opportunity for Collaboration**

- invIoS is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include exclusive licensing assets as a preferred option but also project funding, and research collaborations

---

**Opportunities sought**

- Spinout companies
- Research projects
- Centres of excellence
- Academics and expertise
- Technologies

**Submissions**

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](http://discover.in-part.com)

Deadline: **21st March 2022 - 11:59 pm GMT**

Have any questions? Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

---

invIoS offers unique and highly promising proprietary cell therapy technology platform, and an orally administered novel small molecule for therapy of various cancers. invIoS is a pioneer in development of drug candidates targeting new immune checkpoints such as Cbl-b and in immunomodulation. Learn more about invIoS through this [slide deck](#) and [press release](#).